** U.S.-listed shares of Mereo BioPharma MREO.O MAH0y.F plunge 36.7% to $1.86 and Ultragenyx RARE.O slip 27.7% to $29.95 in extended trading
** Ultragenyx and Mereo say their late-stage trial of setrusumab for a type of genetic disorder would progress to final analysis by year-end
** Co was expected to give interim data from the study in mid-July
** J.P.Morgan analysts said statistical bar for interim analysis was high, and more time will benefit the trial
** Brokerage called the sell-off "a material overreaction," saying after-hours trading "reflects a trial failure scenario"
** An independent safety committee found the experimental drug continues to be well tolerated -RARE
** Co was testing the drug to treat osteogenesis imperfecta, a genetic disorder that makes bones very fragile and easy to break, often from little or no injury, because the body doesn't produce collagen properly
** YTD, RARE down 1.5%, MREO down 16%
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.